Ann: Update - Notification of buy-back - NEU, page-28

well.the study was withdrawn a couple of days ago and that is no small detail.

https://clinicaltrials.gov/study/NCT05879614

Cornerstone support from leading institutional healthcare investors, with total
applications from new and existing shareholders far exceeding A$20 million
• Share Purchase Plan at $2.05 per share for eligible shareholders in Australia and NZ to
raise up to a further A$2m
• Funds raised enable Neuren to accelerate NNZ-2591 towards Phase 3 in four
indications:
o Phase 2 clinical trial for Prader-Willi syndrome, following recent grant of
Orphan Drug designation by FDA
o Phase 3 preparation in parallel with Phase 2 trials – applicable across
Prader-Willi, Phelan-McDermid, Angelman and Pitt Hopkins syndromes

after three years of phase 3 there is still no trace and PW withdrawn.

for those of us who have historical memory, I remember that some institutional in September 2021, subscribed to a capital increase of more than 20 million dollars to accelerate the PW study along with the rest that we know. perhaps that someone who subscribed was disappointed to have learned only verbally and not with an official document as was the case for the success of PMD, Pitt and Angelman, the suspension of the PW trial. now even withdrawn....mahhh